Healthcare decision makers are increasingly concerned about making choices based on value – but they need reliable information on value to do so. More importantly, they need information that is specific to them and reflects the context of the actual decision. Fields like cost-effectiveness analysis provide a strong foundation, but the reality is that existing [...]

Multiple OSVP-based resources are available: Disease-specific decision models: IVI has released two disease-specific OSVP decision models for simulating outcomes and assessing relative value of treatment sequences in rheumatoid arthritis (IVI-RA) and EGFR+ non-small cell lung cancer (IVI-NSCLC). The models are open-source, and source code and R packages are free to download and customize. Users can also [...]

IVI's OSVP value assessment models have a number of key advantages over these other approaches: Rigorous quantitative analysis: Health benefits, risks and costs are quantified explicitly in OSVP models, making comparison of treatment options more straightforward for decision-makers. Patient-centricity: One of IVI’s primary goals is to improve the ability of value assessment to quantify and incorporate [...]

There are many ways to use IVI's open-source models to compare the value of treatment sequences in specific diseases (currently rheumatoid arthritis and EGFR+ non-small cell lung cancer). These include: Web-based Value Tools: Two apps, designed for different kinds of user, are available for each model: Basic: Streamlined tool designed for a general user and [...]

IVI’s disease-specific models currently focus on the relative value of drug therapies and do not include other types of intervention (surgery, for example). To model the relative efficacy of different treatments or interventions, we must first know how the various options compare to one another, which requires reliable clinical evidence from randomized control trials (RCTs). [...]

Yes! When beginning the development of a disease-specific OSVP model, IVI recruits a Clinical Scientific Advisor with relevant expertise to join the modeling team. Dr. Jeff Curtis, a rheumatologist and professor at the University of Alabama Birmingham, serves in this capacity on the IVI-RA decision model. For the IVI-NSCLC decision model, this clinical expertise is [...]

To ensure that simulated outcomes reflect outcomes in routine practice, baseline events rates (i.e., the rate of disease progression, the mortality rate, the rate at which patients discontinue treatment), patient preferences, and costs are modeled using real-world data. To enhance validity, relative treatment effects relative treatment effects (e.g., relative risks, odds ratios, and [...]

We aim to develop models that capture all aspects of value important to the patient. This starts with providing input on our disease-specific models, currently available for rheumatoid arthritis and EGFR+ non-small cell lung cancer. Any feedback you can provide during public comment periods for our models will be considered in modifying the existing versions [...]